Biomay AG Successfully Completes Interim Analysis of Phase IIb Study with the Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32

Biomay announced today that an interim analysis for futility has been successfully completed for an ongoing phase IIb study ( identifier NCT01538979) with its 3rd generation grass pollen allergy vaccine BM32.

Vienna (I-Newswire) December 16, 2013 - The study has enrolled 180 patients and is designed to show a treatment effect over two consecutive pollen seasons. An independent data management committee (DMC) has been appointed to analyze the data from the first treatment year with respect to the primary endpoint combined symptom and medication score (SMS) as well as the safety aspects of the treatment. The DMC has recommended continuation of the study into the next treatment year.

All patients on active treatment will receive the lower of the two initial doses.
Rainer Henning, CEO of Biomay, commented: We are extremely satisfied with the result of this interim analysis of our most advanced product BM32. Reaching this milestone is an important step in the validation of our peptide carrier fusion protein vaccine platform. We are now looking forward with great confidence to the final read-out of the study in the fourth quarter of 2014".

Biomay will welcome a partner for phase III development, registration and marketing of BM32 as well as for the peptide carrier fusion protein platform.

About BM32 and peptide carrier fusion vaccines:
BM32 is an innovative grass pollen allergy vaccine based on recombinant peptide carrier technology invented in the lab of Prof. Rudolf Valenta at the Medical University of Vienna. This is a revolutionary concept, which offers potential for a paradigm shift in the treatment of allergies. The carrier peptide fusion proteins are constructed from the immunogenic viral coat protein PreS from HBV and peptides from the IgE binding epitopes of the allergens in question; the latter have been engineered to lose their IgE binding capacity. BM32 has been designed to protect patients from the debilitating effects of grass pollen exposure and possibly provide long term cure. The product requires only 3 to 4 annual injections and promises to have very limited side effects. The ongoing phase IIb trial is conducted in 11 leading allergy clinics in 6 European countries and has enrolled 180 patients. The study is coordinated by Prof. Johannes Ring (Klinik am Biederstein, Technical University Munich, Germany).

Based on the same technology platform, additional vaccines targeting different allergies (house dust mite, ragweed, birch and cat dander) are in preclinical development and will be advanced to clinical trials in the near future.

About PR&D Public Relations for Research & Development

PR&D - Public Relations for Research & Development

Viennese agency for science-commun   More..ication

We inform 11000 science and business journalists
Our clients have at their disposal individual connections to over 2500 scientific and commercial journalists worldwide. An additional 8600 contacts are made available for them quickly and efficiently through trade-specific news services.

Thus equipped, we offer a singularly effective media work in the field of research and development and attain media attention for our clients in a total of 35 countries in Europe, America and Asia.

PR&D provides for a professional and successful implementation of media strategy starting from individual press releases to the supporting of overall media agendas, both at the national and international levels.Less..

Contact Information

PR&D Public Relations for Research & Development
Till C. Jelitto
Mariannengasse 8
Phone : +43 1 505 70 44


allergy   vaccine   Biomay  

Published in:

Medical > Allergies

Published On:

December 16, 2013

Print Release:

Print Release

If you have questions regarding information in this press release contact the company listed above. is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.

Related Releases

Local Cancer Treatment Center Supports National Cancer Control Month in April
Highlands Oncology Group Supports Awareness For Cancer Control in April

Mark McClure, ARP Wave and Huebner Join Forces in San Antonio
The ARP Wave System, a patented neurological sports rehab program used by the world's most elite professional athletes in getting them back from injury 80% faster than traditional rehab, is finally coming to San Antonio, TX.

Evershore Financial Group Engages Community, Fundraises for Diabetes Research
Evershore employees who have diabetes are thankful for the strong support of their employer.

Quit Smoking To Save Your Money And Life
On May 31 the world watch the world no tobacco day. World Health Organization WHO has told this that 6 million individuals passed on in 2011 because of employments of tobacco.

Teeth Whitening Melbourne - Hollywood Smiles Now Available in Melbourne
Melbourne Dentist Clinic now offers Teeth Whitening Melbourne, which delivers brilliant sparking 'Hollywood' smiles under an hour.